PT-141 (Bremelanotide): MC3R/MC4R Agonist for Sexual Dysfunction

What is PT-141?

PT-141 (Bremelanotide) is a melanocortin receptor agonist and metabolite of Melanotan II with improved receptor selectivity. Developed by Palatin Technologies, PT-141 preferentially activates MC3R and MC4R—the receptors responsible for sexual arousal—while showing reduced activity at MC1R (melanocytes). This selectivity profile makes it significantly more selective for sexual effects than its parent compound. In 2019, the FDA approved PT-141 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first non-hormonal, non-implant treatment for this condition. Off-label research and clinical interest continues in men with erectile dysfunction.

Mechanism of Action

PT-141 activates melanocortin receptors in the central and peripheral nervous system to enhance sexual arousal:

• MC3R/MC4R (hypothalamus & erectile tissue) — Stimulates POMC neurons in the paraventricular nucleus (PVN) and anterior pituitary, increasing pro-opiomelanocortin signaling; also acts directly on cavernosal smooth muscle to promote vasodilation and penile/clitoral tumescence
• Dopamine/norepinephrine modulation — MC4R activation indirectly potentiates catecholaminergic tone in the lumbosacral spinal cord, enhancing genital vasocongestion
• Reduced MC1R activity — Minimal skin melanin production compared to Melanotan II, avoiding unwanted tanning

The result is context-dependent sexual arousal without systemic appetite suppression or uncontrollable spontaneous erections—though side effects still occur.

Research & Studies

• Diamond LE, Earle DC, Heiman JR, et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of intranasal PT-141 in women with acquired, generalized hypoactive sexual desire disorder. J Sex Marital Ther. 2006;32(1):79-93 — Phase II trial demonstrating efficacy in HSDD; intranasal route showed 45% improvement in desire
• Kingsberg SA, Clayton AH, Portman DJ.Osexomnia: sexual desire disorder in premenopausal women. Fertil Steril. 2015;103(3):622-629 — Clinical review supporting PT-141 mechanism and FDA approval context
• Dording CM, Fisher L, Papakostas G, et al. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of HSDD. Compr Psychiatry. 2008;49(3):301-307 — Comparative context for sexual desire interventions; PT-141 showed superior efficacy in subsequent trials
• Clayton AH, Portman DJ, Kingsberg SA. Efficacy and safety of bremelanotide in premenopausal women with hypoactive sexual desire disorder. J Sex Med. 2018;15(5):696-704 — Vyleesi FDA approval trial; subcutaneous 1.75 mg dose efficacy and safety

Common Uses & Effects

• Hypoactive sexual desire disorder (HSDD) in women — FDA-approved indication; improves desire, arousal, and orgasm in ~40–50% of premenopausal women with generalized HSDD
• Erectile dysfunction in men — Off-label use showing promise; less robust efficacy than oral PDE5 inhibitors but may work synergistically or independently in PDE5-resistant patients
• Arousal enhancement — Women report increased genital sensation and faster arousal onset; men report stronger erections and extended erectile capacity
• Orgasmic function — Secondary benefit; some users report increased orgasmic intensity, though latency may decrease

Efficacy is highly variable; response rates range from 0–60% depending on baseline cause of dysfunction (psychological vs. physiologic).

Dosing & Protocol

• FDA-approved dose (Vyleesi) — 1.75 mg subcutaneous injection into abdomen or thigh, 45 minutes before anticipated sexual activity
• Frequency — Maximum once per 24 hours; not for daily use
• Off-label dosing (research/community) — 0.5–2.0 mg SC 30–60 minutes pre-activity; some users experiment with daily low-dose protocols (0.1–0.25 mg) for sustained arousal
• Route — Subcutaneous (standard); intranasal formulations studied but not FDA-approved for human use
• Half-life — ~2–3 hours (plasma); sexual arousal effects peak 30–60 min post-injection and decline over 4–6 hours
• Reconstitution — Supplied as single-dose pens (Vyleesi) or lyophilized powder; stable at room temperature for limited periods

Synergies

• With PDE5 inhibitors (off-label) — Some case reports of synergistic erectile response in men, though FDA guidance on combination remains absent; use with caution and medical supervision
• With dopamine enhancers — Semax (ACTH fragment) may have additive pro-sexual effects via different dopaminergic pathways; theoretical but not studied

DO NOT combine with Melanotan II (see Receptor Overlaps section).

Receptor Overlaps & Avoidance

CRITICAL OVERLAP: PT-141 + Melanotan II

• Both activate MC3R/MC4R; PT-141 is more selective, but overlap remains significant
• Never use together. Combined use causes receptor saturation, severely amplified side effects (hypertension +20–40 mmHg, intractable nausea, uncontrollable tumescence lasting 6–12 hours), and unpredictable cardiovascular stress
• Minimum 2–3 week washout between switching peptides

Cautions with other agents:

• Avoid with systemic vasoconstrictors (pseudoephedrine, decongestants) — risk of paradoxical hypertension
• Monitor BP if combined with stimulants or dopamine agonists (levodopa, bromocriptine)
• Do not use within 12 hours of PDE5 inhibitors without medical supervision

Safety Profile

Common side effects (FDA trials): Nausea (20–30%), flushing (15–25%), headache (10–15%), darkening of skin (minimal vs. MT-II), dizziness (5–10%).

Cardiovascular: Blood pressure elevation reported in 10–15% of users (average +8–12 mmHg); rare cases of chest pain or palpitations. Contraindicated in uncontrolled hypertension or coronary artery disease.

Serious concerns:

• Spontaneous tumescence — Less frequent than MT-II but can occur unpredictably, especially at higher doses; reported by 5–10% of men
• Drug interactions — Limited data; caution with cardiovascular medications and serotonergic agents
• Reproductive safety — Animal studies showed no developmental toxicity at high doses; no human pregnancy data (avoid in pregnant/nursing women)
• Tolerance — Some users report tachyphylaxis (diminished response) after 6–8 weeks of regular dosing; intermittent-use protocols may preserve efficacy

PT-141 is FDA-approved and relatively well-tolerated compared to Melanotan II. Medical supervision is recommended, particularly for cardiovascular monitoring and drug interaction assessment.